Mikkel Rosenvold
11 weeks ago

New obesity drug causes 8% share jump after trial results

Could this drug be even more popular than Ozempic and Wegovy?
Assorted pharmaceutical medicine pills, tablets and capsules over blue background
Kenishirotie, Shutterstock

Danish pharma juggernaut Novo Nordisk has been one of the prime growth cases of the stock market in recent years and their huge success in the obesity drug market could be set for a new boost.

On Thursday’s Capital Markets Day at Novo, the company announced early trial data for the experimental drug Amycretin, which hints at twice as good weight loss results compared to Wegovy – the existing flagship obesity drug from Novo.

Amycretin demonstrated a potential 13% weight loss potential within 12 weeks, whereas Wegovy is limited to 6%. Amycretin and Wegovy belongs to a class of drugs known as GLP-1 agonists, originally designed to treat type 2 diabetes, that have been shown to reduce food cravings and empty the stomach more slowly.

This caused the Novo stock to jump more than 8% on Thursday as investors speculate in the immense global potential of the new obesity drug.

The Novo stock has risen more than 300% since the launch of Wegovy two and a half years ago.

With the recent surge in stock prices, Novo has grown to be the largest company in Europe by market cap, surpassing even French fashion and luxury giant LVMH.

Simultaneously, Novo announced new plans for the expansion of their production capabilities across the globe as the supply of obesity drugs seems to be the main stumbling block for growth and expansion.

Novo Nordisk is also planning a new major research and design facility in Boston, Massachusetts as the hiring and development potential of the local area in the company’s native Denmark is becoming limited as the company continues to grow and expand.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries.

Disclaimer

The information provided by this Site is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.

More News

1 hour ago FX Daily: May 28, 2024 - Currency Movements Signal Mixed Trends Daily update from the foreign exchange market.
3 hours ago US Market Open: May 28, 2024 - Mixed Signals Amid Sector Divergence Daily update from the US market open.
3 hours ago The Western World’s Financial Leaders Met - Here are 7 Central Highlights Discover how the G7's latest meeting addressed global economic challenges, AI integration, and sustainable development.
8 hours ago Chocolate Trade Tiff: EU Fines Oreo and Toblerone Parent for Anticompetitive Practices EU slaps €337.5 million fine on Oreo and Toblerone maker for stifling trade.
8 hours ago Europe Market Open: May 28, 2024 - Mixed Performance Across European Markets Daily update from the European market open.
23 hours ago Dogecoin Dog Has Passed Away Farewell to Kabosu: The Shiba Inu behind the iconic ‘Doge’-meme and Dogecoin
1 day ago Israeli Airstrike Hits Rafah Tent Camp Israeli airstrike on Rafah camp kills dozens, raising international alarm.
1 day ago Meta and Call of Duty Maker Sued by Families of School Shooting Victims Families of the 2022 Uvalde school shooting victims file lawsuits against major corporations and officials, claiming they contributed to the tragedy.
1 day ago Walmart and Capital One Call It Quits on Partnership Walmart and Capital One announce the end of their six-year card partnership amidst legal disputes.